[{"uuid": "79e2a2c2-f515-31e6-aea3-511c00b06791", "title": "All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/know-alto-neuroscience-inc-anro-170013078.html", "providerPublishTime": 1736355613, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/xopQugjeNyS1VO21qlHkcQ--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f", "width": 900, "height": 675, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/rm3.DEH2cLu6ucaTWn4tQA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ANRO"]}, {"uuid": "e027b3fd-8afb-3f5e-98f4-5b06d96dfcb0", "title": "Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/alto-neuroscience-announces-data-presented-130300504.html", "providerPublishTime": 1733922180, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/nlv57F6zxTB8SR91fcBKMw--~B/aD01Mzc7dz0xNjU5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cb0c9c80f60417ff34072d58865a1f4e", "width": 1659, "height": 537, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/yUeVMCmXzzZQ4f8A1mB5SQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cb0c9c80f60417ff34072d58865a1f4e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ANRO"]}, {"uuid": "577599d5-0341-3776-960f-030689f66833", "title": "Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/alto-neuroscience-reports-third-quarter-211000356.html", "providerPublishTime": 1731445800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/bGJy13erXhopAbknSy7a0Q--~B/aD01Mzc7dz0xNjU5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/896663868c8cb43db3b389cf908425c1", "width": 1659, "height": 537, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/fQAciUeaYLTomxewO2xhjQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/896663868c8cb43db3b389cf908425c1", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ANRO"]}, {"uuid": "33f16333-0984-3774-ac43-4d0daae43b47", "title": "Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/allink-biotherapeutics-raises-42m-series-130600365.html", "providerPublishTime": 1732799160, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/eWOT6ICH6q02_6VC48sZaw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/9cd1f8fa845f72732c1869a00ef92b98", "width": 16, "height": 16, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/nXWUGBRuIzHg07pZJJ1ljQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/9cd1f8fa845f72732c1869a00ef92b98", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["WDH", "LAAOF", "LI", "HUYA", "PDD", "BZ"]}]